Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1614804rdf:typepubmed:Citationlld:pubmed
pubmed-article:1614804lifeskim:mentionsumls-concept:C0008059lld:lifeskim
pubmed-article:1614804lifeskim:mentionsumls-concept:C0003402lld:lifeskim
pubmed-article:1614804lifeskim:mentionsumls-concept:C0276609lld:lifeskim
pubmed-article:1614804lifeskim:mentionsumls-concept:C1522537lld:lifeskim
pubmed-article:1614804lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:1614804lifeskim:mentionsumls-concept:C1280519lld:lifeskim
pubmed-article:1614804lifeskim:mentionsumls-concept:C0073010lld:lifeskim
pubmed-article:1614804pubmed:issue1lld:pubmed
pubmed-article:1614804pubmed:dateCreated1992-7-27lld:pubmed
pubmed-article:1614804pubmed:abstractTextThe authors describe the results of the first experience gained with the use of recombinant alpha 2-interferon in children with acute viral hepatitis B. The drug was administered rectally in combination with antioxidants (tocopherol). The study was carried out by the double blind method with randomization and two control groups (given tocopherol alone or placebo alone). 73 children with acute viral hepatitis B were examined. The therapeutic combination reaferon plus tocopherol was established to favour more rapid elimination of dyspeptic and abdominal phenomena, to shorten the time of the liver and spleen size increase, duration of hyperfermentemia, to provide for an accelerated reduction of HBsAg titers, elimination of HBeAg and seroconversion, to stimulate alpha-interferon production by leukocytes, and to activate the system of mononuclear phagocytes.lld:pubmed
pubmed-article:1614804pubmed:languageruslld:pubmed
pubmed-article:1614804pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1614804pubmed:citationSubsetIMlld:pubmed
pubmed-article:1614804pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1614804pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1614804pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1614804pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1614804pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1614804pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1614804pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1614804pubmed:statusMEDLINElld:pubmed
pubmed-article:1614804pubmed:issn0031-403Xlld:pubmed
pubmed-article:1614804pubmed:authorpubmed-author:NikitinaT STSlld:pubmed
pubmed-article:1614804pubmed:authorpubmed-author:MalinovskaiaV...lld:pubmed
pubmed-article:1614804pubmed:authorpubmed-author:Re?zisA RARlld:pubmed
pubmed-article:1614804pubmed:authorpubmed-author:Mikha?lovM...lld:pubmed
pubmed-article:1614804pubmed:authorpubmed-author:NazarenkoI...lld:pubmed
pubmed-article:1614804pubmed:authorpubmed-author:DrondinaA KAKlld:pubmed
pubmed-article:1614804pubmed:authorpubmed-author:MarkarianA...lld:pubmed
pubmed-article:1614804pubmed:authorpubmed-author:ShekhadeSSlld:pubmed
pubmed-article:1614804pubmed:issnTypePrintlld:pubmed
pubmed-article:1614804pubmed:ownerNLMlld:pubmed
pubmed-article:1614804pubmed:authorsCompleteYlld:pubmed
pubmed-article:1614804pubmed:pagination60-4lld:pubmed
pubmed-article:1614804pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:1614804pubmed:meshHeadingpubmed-meshheading:1614804-...lld:pubmed
pubmed-article:1614804pubmed:meshHeadingpubmed-meshheading:1614804-...lld:pubmed
pubmed-article:1614804pubmed:meshHeadingpubmed-meshheading:1614804-...lld:pubmed
pubmed-article:1614804pubmed:meshHeadingpubmed-meshheading:1614804-...lld:pubmed
pubmed-article:1614804pubmed:meshHeadingpubmed-meshheading:1614804-...lld:pubmed
pubmed-article:1614804pubmed:meshHeadingpubmed-meshheading:1614804-...lld:pubmed
pubmed-article:1614804pubmed:meshHeadingpubmed-meshheading:1614804-...lld:pubmed
pubmed-article:1614804pubmed:meshHeadingpubmed-meshheading:1614804-...lld:pubmed
pubmed-article:1614804pubmed:meshHeadingpubmed-meshheading:1614804-...lld:pubmed
pubmed-article:1614804pubmed:meshHeadingpubmed-meshheading:1614804-...lld:pubmed
pubmed-article:1614804pubmed:meshHeadingpubmed-meshheading:1614804-...lld:pubmed
pubmed-article:1614804pubmed:meshHeadingpubmed-meshheading:1614804-...lld:pubmed
pubmed-article:1614804pubmed:meshHeadingpubmed-meshheading:1614804-...lld:pubmed
pubmed-article:1614804pubmed:meshHeadingpubmed-meshheading:1614804-...lld:pubmed
pubmed-article:1614804pubmed:meshHeadingpubmed-meshheading:1614804-...lld:pubmed
pubmed-article:1614804pubmed:meshHeadingpubmed-meshheading:1614804-...lld:pubmed
pubmed-article:1614804pubmed:year1992lld:pubmed
pubmed-article:1614804pubmed:articleTitle[Effectiveness of using recombinant interferon alfa2 (reaferon) combined with antioxidants in children with acute hepatitis B].lld:pubmed
pubmed-article:1614804pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1614804pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:1614804pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:1614804pubmed:publicationTypeRandomized Controlled Triallld:pubmed